Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CytRx has been awarded a grant of approximately $222,000 to develop its inhibitors for the treatment of type 2 diabetes and obesity.
Subscribe to our email newsletter
CytRx was awarded the grant by the National Institute of Diabetes and Digestive and Kidney Diseases, a part of the National Institutes of Heath (NIH), based on the company’s small molecule and structure-based drug design expertise.
Obesity is a major factor in the increased incidence of type 2 diabetes. However, most current therapies for treating type 2 diabetes focus on hyperglycemia control and insulin resistance, rather than obesity.
Elevation of plasma free fatty acid levels is an important clinical feature in type 2 diabetes and obesity. Funds from the SBIR grant will be used by CytRx to further develop potential inhibitors of fatty acid synthase, a target which plays a role in weight gain and insulin responsiveness in type 2 diabetes.
The SBIR Program is intended to support innovative research that has the potential for commercialization.